SGO

Immunotherapy approvals shine light on need for molecular testing in endometrial cancer

February 01, 2022

Sarah Lee, MD, MBA, discusses the use of checkpoint inhibitors in endometrial cancer, research regarding the association between MSI-H, dMMR, and TMB-H disease, and the importance of broad molecular testing to ensure all eligible patients are appropriately matched to immunotherapeutic options.

Secondary cytoreductive surgery in recurrent ovarian cancer

February 01, 2022

Amer Karam, MD, discusses the role of secondary cytoreductive surgery in ovarian cancer and the need for careful patient selection, plus the results from 3 clinical trials and the key differences between these efforts.

Increase of endometrial cancer in Black women prompts questions into underlying causes

January 31, 2022

Cortney Eakin, MD, discusses alarming trends in uterine cancer histologies in Black women and some of the potential underlying risk factors at play.

Is Medicare Dangerous to Your Patient’s Health? If They Have Ovarian Cancer, Yes

March 15, 2011

According to government estimates, the incidence of ovarian cancer is almost 13 per 100,000 women per year, and most cases are diagnosed in an advanced stage. As such, proper treatment is critical to ensure survival. However, Dr Melissa M. Thrall, fellow in the department of obstetrics and gynecology at the University of Washington, found that less than 40% of women reliant on Medicare receive standard care.

Understanding Referral Patterns for Ovarian Cancer

March 14, 2011

Primary care physicians are the entry point for care for many patients. They are often responsible for determining when additional expertise is needed and to which specialist a patient should go for additional care. Although studies have shown that gynecologic oncologists can improve surgical and survival outcomes for patients with ovarian cancer, the referral rate from primary care physicians to gynecologic oncologists remains relatively low.